z-logo
open-access-imgOpen Access
Genetic diversity of human immunodeficiency virus-1 in Nigeria: 2002–2017 – systematic review and meta-analysis
Author(s) -
Mohammed Ibrahim Tahir,
Maryam Aminu,
Babangida Ahmed Suleiman,
Ahmed Saraja Opaluwa,
Abdurrahman Elfulaty Ahmad
Publication year - 2020
Publication title -
nigerian postgraduate medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 19
ISSN - 1117-1936
DOI - 10.4103/npmj.npmj_64_19
Subject(s) - meta analysis , confidence interval , funnel plot , virology , human immunodeficiency virus (hiv) , medicine , forest plot , genetic diversity , biology , demography , publication bias , environmental health , population , sociology
Nigeria was ranked second highest country with human immunodeficiency virus (HIV) burden worldwide. HIV-1 subtypes and circulating recombinant forms genetic variability affect the protease and reverse transcriptase genes which code for viral enzymes and are the main targets for antiretroviral drugs. Therefore, this study was aimed at reviewing and pooling such HIV-1 subtypes in Nigeria to represent the collective prevalence of each subtype. Studies of HIV-1 subtypes in Nigeria published from 2002 to 2017 were retrieved and synthesised from different sources electronically. Sixteen studies were included for random effect meta-analysis for various subtypes in each study. The pooled prevalence was charted in forest plot and effect estimates from individual studies against some measure of study size or precision were presented in funnel plots. The pooled prevalence of Subtype G, CRF02_AG, CRF06_cpx, Subtype A and Subtype C were 38.27% (95% Confidence Interval [CI]: 21.27%- 55.98%), 37.81% (95% CI: 20.37%- 55.25%), 6.6% (95% CI: 7.10%-7.10%), 14.05% (95% CI: 9.06% - 19.04%) and 2.80% (95% CI: 2.70%- 8.30%) respectively. This study suggests HIV-1 subtypes G, CRF02_AG and A are the most prevalent in Nigeria.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here